Disrupting tumour blood vessels GM Tozer, C Kanthou, BC Baguley Nature Reviews Cancer 5 (6), 423-435, 2005 | 1135 | 2005 |
The biology of the combretastatins as tumour vascular targeting agents GM Tozer, C Kanthou, CS Parkins, SA Hill International journal of experimental pathology 83 (1), 21-38, 2002 | 408 | 2002 |
The tumor vascular targeting agent combretastatin A–4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells C Kanthou, GM Tozer Blood, The Journal of the American Society of Hematology 99 (6), 2060-2069, 2002 | 357 | 2002 |
Expression of vascular endothelial growth factor receptors in smooth muscle cells A Ishida, J Murray, Y Saito, C Kanthou, O Benzakour, M Shibuya, ... Journal of cellular physiology 188 (3), 359-368, 2001 | 326 | 2001 |
Use of low molecular weight heparin in pregnancy E Melissari, CJ Parker, NV Wilson, G Monte, C Kanthou, KD Pemberton, ... Thrombosis and Haemostasis 68 (12), 652-656, 1992 | 246 | 1992 |
Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies C Kanthou, GM Tozer International journal of experimental pathology 90 (3), 284-294, 2009 | 226 | 2009 |
The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death C Kanthou, O Greco, A Stratford, I Cook, R Knight, O Benzakour, G Tozer The American journal of pathology 165 (4), 1401-1411, 2004 | 167 | 2004 |
The endothelial cytoskeleton as a target of electroporation-based therapies C Kanthou, S Kranjc, G Sersa, G Tozer, A Zupanic, M Cemazar Molecular cancer therapeutics 5 (12), 3145-3152, 2006 | 148 | 2006 |
Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform–producing tumors GM Tozer, S Akerman, NA Cross, PR Barber, MA Björndahl, O Greco, ... Cancer research 68 (7), 2301-2311, 2008 | 125 | 2008 |
Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth KT Al-Jamal, WT Al-Jamal, S Akerman, JE Podesta, A Yilmazer, JA Turton, ... Proceedings of the National Academy of Sciences 107 (9), 3966-3971, 2010 | 122 | 2010 |
Atherosclerosis and thrombosis: lessons from animal models L Badimon Thrombosis and Haemostasis 86 (07), 356-365, 2001 | 113 | 2001 |
Limitations of the reporter green fluorescent protein under simulated tumor conditions C Coralli, M Cemazar, C Kanthou, GM Tozer, GU Dachs Cancer research 61 (12), 4784-4790, 2001 | 109 | 2001 |
Radiation effects on the cytoskeleton of endothelial cells and endothelial monolayer permeability D Gabryś, O Greco, G Patel, KM Prise, GM Tozer, C Kanthou International Journal of Radiation Oncology* Biology* Physics 69 (5), 1553-1562, 2007 | 108 | 2007 |
Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders SM Kanse, O Benzakour, C Kanthou, C Kost, HR Lijnen, KT Preissner Arteriosclerosis, thrombosis, and vascular biology 17 (11), 2848-2854, 1997 | 100 | 1997 |
Tumour targeting by microtubule-depolymerising vascular disrupting agents C Kanthou, GM Tozer Expert opinion on therapeutic targets 11 (11), 1443-1457, 2007 | 97 | 2007 |
Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro JB Hansen, B Svensson, R Olsen, M Ezban, B Østerud, RH Paulssen Thrombosis and haemostasis 83 (06), 937-943, 2000 | 94 | 2000 |
Tumour vascular disrupting agents: combating treatment resistance GM Tozer, C Kanthou, G Lewis, VE Prise, B Vojnovic, SA Hill The British journal of radiology 81 (special_issue_1), S12-S20, 2008 | 91 | 2008 |
Thrombin‐induced proliferation and expression of platelet‐derived growth factor‐A chain gene in human vascular smooth muscle cells C Kanthou, G Parry, E Wijelath, VV Kakkar, C Demoliou-Mason FEBS letters 314 (2), 143-148, 1992 | 91 | 1992 |
Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions O Greco, S Rossiter, C Kanthou, LK Folkes, P Wardman, GM Tozer, ... Molecular cancer therapeutics 1 (2), 151-160, 2001 | 85 | 2001 |
Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale S Harris, M Craze, J Newton, M Fisher, DT Shima, GM Tozer, C Kanthou PloS one 7 (5), e35231, 2012 | 81 | 2012 |